STRATICYTE™ Test
OtherAssessment for risk of progression to oral cancer
Other names: S100A7 Immunohistochemistry Signature-based Test
NCT Number: NCT05853783
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.
Interested in participating?
Request Info18 year and older
All sexes
Observational
The University of Alabama at Birmingham, Birmingham, Alabama, United States
The study objectives are to:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Assessment for risk of progression to oral cancer
Other names: S100A7 Immunohistochemistry Signature-based Test
Time frame: 5 years
Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy
Time frame: 5 years
Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTE™ classification of Low- and Elevated-Risk.
Time frame: 5 years
Area under the receiver operator curve
Time frame: 5 years
From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant.
Contact information is provided by the study sponsor or research team.
Jason TK Hwang, HBSc, MSc, PhD
CONTACT
Jody Filkowski, BSc, MSc, PhD
CONTACT
Proteocyte Diagnostics Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00540774
Gingival Diseases, Gingivitis
Irvine, California, United States
View Trial DetailsNCT06888453
Gingival Diseases, Gingivitis
Baghdad, Iraq
View Trial DetailsNCT06792812
Bleeding Gum, Gingival Diseases
Baghdad, Iraq
View Trial DetailsNCT06536322
Alzheimer Disease, Brain Diseases
Leuven, Belgium
View Trial Details